CalciMedica, Inc. (CALC) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$1.08

From 52W high−96.97%

Volume18042.00

Market cap$6.96M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$1.08

From 52W high

−96.97%

Volume

18042.00

Market cap

$6.96M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.6x

P/E (TTM)

—

RSI (14)

16.9

MomentumView details →

1D Return

−1.92%

YTD Return

−96.90%

SummaryUpdated Jun 1, 2026

CalciMedica, Inc. (NASDAQ:CALC) is a clinical-stage biotechnology company founded to develop innovative therapies for life-threatening inflammatory diseases. Based in La Jolla, California, the company went public in June 2023 and focuses on a proprietary technology platform that targets calcium release-activated calcium (CRAC) channels to modulate immune responses and protect against tissue damage in severe inflammatory conditions. CalciMedica represents an emerging player in the specialized field of calcium channel inhibition for therapeutic applications.

Ask drillr about CalciMedica, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.6x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.3x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−385.27%

ROA (TTM)

−108.91%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

+9.85%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−61.48%

EBITDA YoY

+1.23%

MomentumView details →

1D Return

−1.92%

YTD Return

−96.90%

1Y Return

−93.61%

RSI (14)

16.9

vs 50D SMA

−51.77%

vs 200D SMA

−80.81%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

5.58x

Quick Ratio

5.58x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.45

EPS Surprise

−57.89%

Beats (12Q)

7/12

Next Q EPS Est

−$1.05

Avg Surprise (4Q)

−7.90%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−21.24M

Op. CF (TTM)

−19.11M

Next earningsNov 11, 2026 →

Latest newsMore news →

Stephen Bardin resigned as CalciMedica, Inc.’s chief financial officer, principal accounting officer and principal financial officer.3d ago

CalciMedica, Inc. elected Allan Shaw and Robert N. Wilson as Class III directors, effective August 19, 2026.61d ago

Similar companies

Ainos, Inc.AIMD Senti Biosciences, Inc.SNTI Skye Bioscience, Inc.SKYE Exicure, Inc.XCUR CollPlant Biotechnologies Ltd.CLGN Aprea Therapeutics, Inc.APRE Find similar companies →

Latest newsMore news →

Stephen Bardin resigned as CalciMedica, Inc.’s chief financial officer, principal accounting officer and principal financial officer.3d ago CalciMedica, Inc. elected Allan Shaw and Robert N. Wilson as Class III directors, effective August 19, 2026.61d ago